09 Mar Avandia, Actos Diabetes Drugs Double Heart Failure Risk
Friday, July 27, 2007
Diabetes patients who take the diabetes drugs Avandia or Actos are two times as likely to develop heard problems
According to a report published in the August issue of Diabetes Care, for every 100 people taking either drug, two will develop heart failure within 26 months.
A U.S. government review released Thursday found Avandia’s heart risks are far higher than Actos’. An advisory panel hearing Monday will examine whether Avandia’s cardiovascular risks warrant a stronger warning label.
Avandia (rosiglitazone) and Actos (pioglitazone) are from the same family of diabetes drugs and used by more than 3 million diabetic patients across the United States.
Sorry, the comment form is closed at this time.